SAN FRANCISCO – Wall Street isn't happy with oncology med-tech Novocure Ltd. The St. Helier, Jersey-based company is working to secure Medicaid reimbursement for its FDA-approved glioblastoma indication – and to move into other solid tumors – all while working to breakeven on its cash in hand. Investors remain skeptical, having driven Novocure's valuation down by more than two-thirds since its IPO in October 2015 – and off 10 percent in just the first few weeks of this year. It's offer price at IPO was $22, but since then shares have descended to almost $7....
SAN FRANCISCO – Wall Street isn't happy with oncology med-tech Novocure Ltd. The St. Helier, Jersey-based company is working to secure Medicaid reimbursement for its FDA-approved glioblastoma indication – and to move into other solid tumors – all while working to breakeven on its cash in hand.
SAN FRANCISCO – A panel spanning regulator, payer, provider and academic interests celebrated the rapid proliferation of diagnostics based on emerging kinds of data that could enable more precise, earlier and better patient treatment. Starting with genomics, this data intensity has rapidly proliferated into all sorts of 'omics analyses, including proteomics, pharmacogenomics, metabolomics and microbiomics. Much of this work remains at the research stage, but panelists from the FDA, the Mayo Clinic, the Blue Cross Blue Shield Association and San Diego-based Illumina Inc. spinout Grail Inc. mused on various issues facing this part of the...
SAN FRANCISCO – IBM Watson Health was a star at this year's J.P. Morgan Healthcare conference, announcing two deals with high profile players. The latest was with the U.S. FDA to work together to define a way for to exchange health data across a variety of technology platforms with an initial focus on oncology data.
SAN FRANCISCO – A panel spanning regulator, payer, provider and academic interests celebrated the rapid proliferation of diagnostics based on emerging kinds of data that could enable more precise, earlier and better patient treatment. Starting with genomics, this data intensity has rapidly proliferated into all sorts of 'omics analyses, including proteomics, pharmacogenomics, metabolomics and microbiomics.
